| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MBL2 |
| Uniprot No | P11226 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 21-248aa |
| 氨基酸序列 | ETVTCEDAQKTCPAVIACSSPGINGFPGKDGRDGTKGEKGEPGQGLRGLQ GPPGKLGPPGNPGPSGSPGPKGQKGDPGKSPDGDSSLAASERKALQTEMA RIKKWLTFSLGKQVGNKFFLTNGEIMTFEKVKALCVKFQASVATPRNAAE NGAIQNLIKEEAFLGITDEKTEGQFVDLTGNRLTYTNWNEGEPNNAGSDE DCVLLLKNGQWNDVPCSTSHLAVCEFPIVDHHHHHH |
| 预测分子量 | 25 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
nan
Mannose-binding lectin 2 (MBL2) recombinant protein is a genetically engineered version of a naturally occurring pattern recognition molecule critical to innate immunity. MBL2. encoded by the MBL2 gene in humans, belongs to the collectin family and plays a key role in pathogen surveillance. Structurally, it forms oligomers composed of identical subunits, each containing a cysteine-rich N-terminal domain, a collagen-like helical region, and a carbohydrate recognition domain (CRD). The CRD binds to repetitive sugar patterns (e.g., mannose, N-acetylglucosamine) on microbial surfaces, enabling opsonization and activation of the lectin complement pathway via associated serine proteases (MASPs).
Recombinant MBL2 is produced in expression systems such as mammalian cells or yeast to mimic the native protein’s functional glycosylation. Its therapeutic development stems from clinical observations linking MBL2 deficiency (caused by genetic polymorphisms) to increased susceptibility to infections, autoimmune disorders, and severe outcomes in sepsis or COVID-19. By supplementing low MBL levels, the recombinant protein aims to restore immune defense in immunocompromised individuals.
Research highlights its potential in treating antibiotic-resistant infections, modulating inflammatory responses, and enhancing vaccine efficacy. However, challenges include optimizing pharmacokinetics, minimizing immunogenicity, and ensuring consistent oligomerization for functional activity. Current clinical trials focus on safety, dosing, and efficacy in specific populations, while biotechnological advances explore fusion proteins or engineered variants to improve stability and targeting. Overall, MBL2 recombinant protein represents a promising biologic bridging innate immunity and therapeutic innovation.
×
